Fig 1: Role of CCN1 in pathological angiogenesis and clinical correlation with integrin/Hippo pathway.(A) LLC allograft tumour tissues in WT and Ccn1-EC-specific TG mice were extracted at 10 days after inoculation, sectioned, and immunostained with anti-CD31 and anti-PDGFß antibodies and green and red fluorescently labelled secondary antibodies. Stained cells were quantified in the central and peripheral regions. Scale bar = 100 µm. *p<0.05, **p<0.01. (B) The same sectioned tissues as in (A) immunostained with anti-VEGFR2 and CD31. Quantitation was performed in the central and peripheral regions of the tissues. The number of sprouting sites was normalised to the total vessel length. Scale bar = 50 µm. *p<0.05, **p<0.01. (C) The difference in the survival curves of the two groups, CCN1 high (red line) and CCN1 low (blue line) 25% of patients with highest and lowest mRNA expression levels, respectively, n = 126/group] was evaluated using log-rank test with Kaplan–Meier estimation. p=8.7 × 10-3 between two groups. (D) Box plots of normalised mRNA expression levels of ITGB3, VEGFR2, DLL4, YAP, and WWTR1 in CCN1-high and CCN1-low groups.